|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Douaiher J, Ravipati A, Grams B, Chowdhury
S, Alatise O and Are C: Colorectal cancer-global burden, trends,
and geographical variations. J Surg Oncol. 115:619–630. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Islami F, Siegel RL, Ward EM and
Jemal A: Global cancer in women: Burden and trends. Cancer
Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ministry of Health Welfare: The cause of
death in Taiwan in 2016. http://www.mohw.gov.tw/cp-16-33598-1.htmlAugust
25–2017
|
|
6
|
National Comprehensive Cancer Network:
Rectal Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines). version 2. 2019.
|
|
7
|
Hawkins AT, Ford MM, Geiger TM, Hopkins
MB, Kachnic LA, Muldoon RL and Glasgow SC: Neoadjuvant radiation
for clinical T4 colon cancer: A potential improvement to overall
survival. Surgery. 165:469–475. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. New York;
Springer-Verlag: 2010
|
|
9
|
Ma SC, Zhao Y, Zhang T, Ling XL and Zhao
D: Association between the ERCC1 rs11615 polymorphism and clinical
outcomes of oxaliplatin-based chemotherapies in gastrointestinal
cancer: A meta-analysis. Onco Targets Ther. 8:641–648.
2015.PubMed/NCBI
|
|
10
|
Huang MY, Tsai HL, Lin CH, Huang CW, Ma
CJ, Huang CM, Chai CY and Wang JY: Predictive value of ERCC1,
ERCC2, and XRCC1 overexpression for stage III colorectal cancer
patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol.
108:457–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amshel C, Avital S, Miller A, Sands L,
Marchetti F and Hellinger M: T4 rectal cancer: Analysis of patient
outcome after surgical excision. Am Surg. 71:901–903; discussion
904. 2005.PubMed/NCBI
|
|
12
|
Diaconescu M, Burada F, Mirea CS, Moraru
E, Ciorbagiu MC, Obleaga CV and Vilcea ID: T4 Colon cancer-current
management. Curr Health Sci J. 44:5–13. 2018.PubMed/NCBI
|
|
13
|
Gao P, Song YX, Wang ZN, Xu YY, Tong LL,
Sun JX, Yu M and Xu HM: Is the prediction of prognosis not improved
by the seventh edition of the TNM classification for colorectal
cancer? Analysis of the surveillance, epidemiology, and end results
(SEER) database. BMC Cancer. 13:1232013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gunderson LL, Jessup JM, Sargent DJ,
Greene FL and Stewart AK: Revised TN categorization for colon
cancer based on national survival outcomes data. J Clin Oncol.
28:264–271. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang C-M, Huang M-Y, Ma C-J, Yeh Y-S,
Tsai H-L, Huang C-W, Huang C-J and Wang J-Y: Neoadjuvant FOLFOX
chemotherapy combined with radiotherapy followed by radical
resection in patients with locally advanced colon cancer. Radiat
Oncol. 12:482017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu CY, Huang CW, Wu IC, Tsai HL, Ma CJ,
Yeh YS, Chang SF, Huang ML and Wang JY: Clinical implication of
UGT1A1 promoter polymorphism for irinotecan dose escalation in
metastatic colorectal cancer patients treated with bevacizumab
combined with FOLFIRI in the first-line setting. Transl Oncol.
8:474–479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tirkes T, Hollar MA, Tann M, Kohli MD,
Akisik F and Sandrasegaran K: Response criteria in oncologic
imaging: Review of traditional and new criteria. Radiographics.
33:1323–1341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang MY, Huang JJ, Huang CM, Lin CH, Tsai
HL, Huang CW, Chai CY, Lin CY and Wang JY: Relationship between
expression of proteins ERCC1, ERCC2, and XRCC1 and clinical
outcomes in patients with rectal cancer treated with FOLFOX-based
preoperative chemoradiotherapy. World J Surg. 41:2884–2897. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang H, Yu X, Xiao WW, Wang QX, Zhou WH,
Zeng ZF, Ding PR, Li LR and Gao YH: Neoadjuvant chemoradiotherapy
followed by surgery in patients with unresectable locally advanced
colon cancer: A prospective observational study. Onco Targets Ther.
11:409–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li L and Ma BB: Colorectal cancer in
Chinese patients: Current and emerging treatment options. Onco
Targets Ther. 7:1817–1828. 2014.PubMed/NCBI
|
|
22
|
National Comprehensive Cancer Network:
Colon cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines). version 2. 2019.
|
|
23
|
Gezen C, Kement M, Altuntas YE, Okkabaz N,
Seker M, Vural S, Gumus M and Oncel M: Results after multivisceral
resections of locally advanced colorectal cancers: An analysis on
clinical and pathological t4 tumors. World J Surg Oncol. 10:392012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lehnert T, Methner M, Pollok A, Schaible
A, Hinz U and Herfarth C: Multivisceral resection for locally
advanced primary colon and rectal cancer: An analysis of prognostic
factors in 201 patients. Ann Surg. 235:217–225. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Foxtrot Collaborative Group, : Feasibility
of preoperative chemotherapy for locally advanced, operable colon
cancer: The pilot phase of a randomised controlled trial. Lancet
Oncol. 13:1152–1160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dehal A, Graff-Baker AN, Vuong B, Fischer
T, Klempner SJ, Chang SC, Grunkemeier GL, Bilchik AJ and Goldfarb
M: Neoadjuvant chemotherapy improves survival in patients with
clinical T4b colon cancer. J Gastrointest Surg. 22:242–249. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grossmann I, Klaase JM, Avenarius JK, de
Hingh IH, Mastboom WJ and Wiggers T: The strengths and limitations
of routine staging before treatment with abdominal CT in colorectal
cancer. BMC Cancer. 11:4332011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takano S, Kato J, Yamamoto H, Shiode J,
Nasu J, Kawamoto H, Okada H and Shiratori Y: Identification of risk
factors for lymph node metastasis of colorectal cancer.
Hepatogastroenterology. 54:746–750. 2007.PubMed/NCBI
|
|
29
|
Larkin JO and O'Connell PR: Multivisceral
resection for T4 or recurrent colorectal cancer. Dig Dis. 30 (Suppl
2):S96–S101. 2012. View Article : Google Scholar
|
|
30
|
Olaussen KA, Dunant A, Fouret P, Brambilla
E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH,
et al: DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grimminger PP, Shi M, Barrett C, Lebwohl
D, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, Winder T and
Lenz HJ: TS and ERCC-1 mRNA expressions and clinical outcome in
patients with metastatic colon cancer in CONFIRM-1 and −2 clinical
trials. Pharmacogenomics J. 12:404–411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee SM, Falzon M, Blackhall F, Spicer J,
Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B,
et al: Randomized prospective biomarker trial of ERCC1 for
comparing platinum and nonplatinum therapy in advanced
non-small-cell lung cancer: ERCC1 trial (ET). J Clin Oncol.
35:402–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Raymond E, Faivre S, Chaney S, Woynarowski
J and Cvitkovic E: Cellular and molecular pharmacology of
oxaliplatin. Mol Cancer Ther. 1:227–235. 2002.PubMed/NCBI
|
|
34
|
Rosell R, Mendez P, Isla D and Taron M:
Platinum resistance related to a functional NER pathway. J Thorac
Oncol. 2:1063–1066. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gossage L and Madhusudan S: Current status
of excision repair cross complementing-group 1 (ERCC1) in cancer.
Cancer Treat Rev. 33:565–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Noda E, Maeda K, Inoue T, Fukunaga S,
Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K,
et al: Predictive value of expression of ERCC 1 and GST-p for
5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal
cancer. Hepatogastroenterology. 59:130–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shirota Y, Stoehlmacher J, Brabender J,
Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg
PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict
survival for colorectal cancer patients receiving combination
oxaliplatin and fluorouracil chemotherapy. J Clin Oncol.
19:4298–4304. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang PM, Tzeng CH, Chen PM, Lin JK, Lin
TC, Chen WS, Jiang JK, Wang HS and Wang WS: ERCC1 codon 118 C->T
polymorphism associated with ERCC1 expression and outcome of
FOLFOX-4 treatment in Asian patients with metastatic colorectal
carcinoma. Cancer Sci. 100:278–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Basso M, Strippoli A, Orlandi A, Martini
M, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A,
Larocca LM and Barone C: KRAS mutational status affects
oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1
expression in metastatic colorectal cancer patients. Br J Cancer.
108:115–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ishibashi K, Okada N, Ishiguro T, Kuwabara
K, Ohsawa T, Yokoyama M, Kumamoto K, Haga N, Mori T, Yamada H, et
al: The expression of thymidylate synthase (TS) and excision repair
complementing-1 (ERCC-1) protein in patients with unresectable
colorectal cancer treated with mFOLFOX6 therapy. Gan To Kagaku
Ryoho. 37:2532–2535. 2010.(In Japanese). PubMed/NCBI
|
